The association between old age and anemia has been recognized for decades. But does it occur because aging causes anemia or because specific age-related diseases bring it on? Recent population-based surveys have renewed the debate and have even referred to the high prevalence of anemia among elderly people as a “public health crisis.” Many of us, schooled before the availability of erythropoiesis-stimulating agents, were taught that anemia is often a concomitant of chronic disease and perhaps aging. Thus, we were admonished not to try to correct anemia but rather to treat the underlying cause.

Recent studies have called into question the role of anemia in cognitive and physical dysfunction and mortality among elderly patients, independent of the underlying cause. The study by den Elzen and colleagues adds further information about the role of anemia in their carefully designed and executed analysis of data from the Leiden 85-plus Study. Their study appears to confirm that mortality is associated with anemia, even after adjustment for important covariates, despite the fact that adjustment for comorbidity largely neutralized the deleterious effects of anemia on both cognitive and physical function. Furthermore, they showed a clear dose–response relation between increasing severity of anemia and risk of death. In other words, anemia appeared to be an independent predictor of mortality. However, with respect to functional decline over time, the authors could not discern whether anemia constituted an intermediate step in the causal pathway from chronic disease to decline in function.

Although the mortality rates were similar among people without anemia and among those whose anemia was corrected during the study period, we have no information as to whether the correction was obtained by treating the underlying disease or by raising the hemoglobin level. If the hemoglobin level was increased, the possibility of intervening via transfusion or erythropoiesis-stimulating agents becomes pertinent in elderly patients.

Anemia in elderly people appears to have multiple etiologies, including nutritional deficiencies and chronic disease. Nevertheless, the cause of about one-third of cases remain unexplained, and there is usually only a mild decrease in the hemoglobin level. Possible mechanisms of unexplained anemia of aging include a blunted erythropoietic response in the setting of iron deficiency, higher circulating levels of proinflammatory cytokines (e.g. IL6, which may reduce erythropoietin levels), decreased androgen levels, and decreased proliferative and regenerative capacity of bone marrow stem cells. Furthermore, although not a concomitant of normal aging, myelodysplasia, which is more common in elderly people, is associated with reduced life-expectancy and is often included in the group of “unexplained” anemias.

Three decades ago, the possibility of a benign form of so-called “senile anemia,” unexplained by other known causes, was raised. Because elderly people have less need for oxygen transport than do active younger people, the authors argue that there was little urgency in treating this type of anemia. However, the question of whether aging (as opposed to disease) causes anemia has recently become more relevant, given the possibility of treatment without blood transfusion.

If anemia is due to a lack of iron, B12, or folate, we can correct the deficiency and, if possible, treat the underlying cause. In the current study, excluding people taking B12, folate and iron supplementation did not change the overall rate of mortality, suggesting that nutritional causes do not necessarily contribute to the excess mortality observed.

Clinical studies in both chronic kidney disease and cancer have shown improvement in health-related quality of life following treatment of anemia with erythropoiesis-stimulating agents. However, this benefit comes at a cost, because hemoglobin correction to nonanemic levels may be associated with increased mortality. Moreover, it has even been argued that anemia of chronic disease is an adaptive response and that efforts to correct the hemoglobin level may be futile at best or harmful at worst.

For unexplained anemia in elderly patients, we may never be able to disentangle whether the underlying cause or the anemia is responsible for death. In their study, den Elzen and colleagues corrected for as many factors as possible, but the risk of residual confounding by underlying disease remains. A randomized clinical trial involving elderly people showed that subcutaneous epoetin alfa was associated with a rise in hemoglobin and a statistically significant improvement in fatigue and anemia (on subscales of the FACIT questionnaire). However, this small trial, despite showing benefits in quality of life, was seriously underpowered to detect any effect on risk of death. Subsequent studies will need to address this question, especially among patients aged 85 or more years, among who, as shown in the

Key points
- Anemia in the elderly is associated with decreased function and increased mortality.
- It is not yet known if this association indicates causality.
- Randomized trials of anemia correction should demonstrate that treatment does more good than harm by examining clinically important outcomes.

From the Department of Hematology and School of Public Health (Paltiel), Hadassah-Hebrew University, Jerusalem, Israel; the Faculty of Health Sciences Ben-Gurion-University of the Negev, Israel, and the Division of Geriatric Medicine (Clarfield), McGill University, Montréal, Que.

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
Leiden study, have a high risk of death (> 8% per year).

Unexplained anemia in elderly people is usually characterized by a mild decrease in hemoglobin. As such, a helpful finding in the study by den Elzen and colleagues is that the risk of death was significantly elevated in the adjusted models only when anemia was severe (hemoglobin < 100 g/L for women and < 110 g/L for men). This finding implies that the causes of anemia in this group are primary bone marrow failure or severe disease and not the “unexplained” anemias of the elderly. It also suggests that trials of hemoglobin correction should focus on this group.

Elderly people may also want a voice in their treatment, given the competing risks and benefits. It is possible that some patients might choose the quality of life and functional improvements despite the increased risk of death.

Physicians should be alert to the possible role of interested parties, including industry, who push for unexplained anemia to be considered a treatable condition. Elderly people constitute a large and growing target for those seeking new markets. Let us first insist on proof that correction of anemia in elderly patients (beyond the treatment of underlying causes) does more good than harm.

Competing interests: Ora Paltiel received a grant from Roche Pharmaceuticals in 2004 for $10 000. None declared for A. Mark Clarfield.

Contributors: Both of the authors contributed to the conception of the article, revised it critically for important intellectual content and approved the final version submitted for publication.

REFERENCES
1. Guralnik JM, Ershler WB, Schrier SL, et al. Anemia in the elderly: a public health crisis in hematology. Hematology Am Soc Hematol Educ 2005:528-32.
2. den Elzen WPJ, Willems JM, Westendorp RGJ, et al. Effect of anemia and comorbidity on functional status and mortality in old age: results from the Leiden 85+-plus Study. CMAJ 2009;DOI:10.1503/cmaj.090040.
3. Eisenstaedt R, Penninx BWJH, Woodman RC. Anemia in the elderly: current understanding and emerging concepts. Blood Rev 2006;20:213-26.
4. Makipour S, Kanapuru B, Ershler WB. Unexplained anemia in the elderly. Semin Hematol 2008;45:250-4.
5. Burch GE. Of senile anemia. Am Heart J 1980;100:407.
6. Lelebvre P, Vekeman F, Sarokhan B, et al. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin 2006;22:1929-37.
7. Patrick DL, Gagnon DD, Zagari MJ, et al.; Epoetin Alfa Study Group. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2005:39:335-45.
8. Tonelli M, Hemmelgarn B, Reisman T. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009;180:E63-E71.
9. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42.
10. Phrommintikul A, Haas SJ, Elik M, et al. Mortality and target haemoglobin concentrations in anemic patients with chronic kidney disease treated with erythropoetin: a meta-analysis. Lancet 2007;369:381-9.
11. Zarychanski R, Houston DS. Anemia of chronic disease: A harmful disorder or an adaptive, beneficial response? CMAJ 2008;179:333-7.
12. Agnihotri P, Telfer M, Butti Z, et al. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa. J Am Geriatr Soc 2007;55:1557-65.

Correspondence to: Dr. A. Mark Clarfield, Department of Geriatrics, Soroka Hospital, Ben-Gurion University, PO Box 151, Beersheva 84101, Israel; fax: 972-8-628-6599; markclar@bgu.ac.il

Peer Review Congress
September 10-12, 2009

Research will be presented on the following topics:
- Mechanisms of peer review and decision making used by journals and funders
- Evaluations of the quality of scientific information
- Biases, breakdowns, and other weaknesses
- Ethical concerns for authors, reviewers, and editors
- Authorship, conflicts of interest, and responsibility for published material
- Open access, new tools and metrics, and the future of scientific publication

For more information
Annette Flanagin
jama-peer@jama-archives.org

Details available at www.jama-peer.org